Is PHVS or PRAX more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Praxis Precision Medicines N/A -34.15% -32.42%

Does the media refer more to PHVS or PRAX?

In the previous week, Pharvaris had 30 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 34 mentions for Pharvaris and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.55 beat Pharvaris' score of 0.48 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KYMR or PHVS?

In the previous week, Pharvaris had 25 more articles in the media than Kymera Therapeutics. MarketBeat recorded 34 mentions for Pharvaris and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.73 beat Pharvaris' score of 0.48 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PTGX or PHVS?

In the previous week, Pharvaris had 23 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 34 mentions for Pharvaris and 11 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.65 beat Pharvaris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PHVS or IONS?

In the previous week, Pharvaris had 21 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 34 mentions for Pharvaris and 13 mentions for Ionis Pharmaceuticals. Pharvaris' average media sentiment score of 0.48 beat Ionis Pharmaceuticals' score of 0.33 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PHVS or CYTK more profitable?

Pharvaris has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Cytokinetics -1,321.12% N/A -51.01%

Does the media refer more to PHVS or CYTK?

In the previous week, Pharvaris had 17 more articles in the media than Cytokinetics. MarketBeat recorded 34 mentions for Pharvaris and 17 mentions for Cytokinetics. Pharvaris' average media sentiment score of 0.48 beat Cytokinetics' score of 0.37 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 12 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pharvaris (PHVS) Competitors

$37.55 -0.51 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$37.45 -0.10 (-0.27%)

As of 05:46 PM Eastern

Compare

PHVS vs. PRAX, KYMR, PTGX, IONS, and CYTK

Should you buy Pharvaris stock or one of its competitors? Pharvaris's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Ionis Pharmaceuticals (IONS), and Cytokinetics (CYTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharvaris compare to Praxis Precision Medicines?

Pharvaris (NASDAQ:PHVS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Praxis Precision Medicines' return on equity of -34.15% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Pharvaris has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Praxis Precision Medicines	$8.55M	1,009.01	-$303.27M	-$12.93	N/A

Pharvaris presently has a consensus target price of $59.87, suggesting a potential upside of 59.43%. Praxis Precision Medicines has a consensus target price of $585.95, suggesting a potential upside of 89.63%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

In the previous week, Pharvaris had 30 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 34 mentions for Pharvaris and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.55 beat Pharvaris' score of 0.48 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharvaris has a beta of -2.33, meaning that its share price is 333% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Kymera Therapeutics presently has a consensus target price of $131.63, suggesting a potential upside of 13.15%. Pharvaris has a consensus target price of $59.87, suggesting a potential upside of 59.43%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Pharvaris has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Pharvaris	N/A	-61.40%	-56.00%

Pharvaris has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	246.69	-$311.35M	-$3.24	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 25 more articles in the media than Kymera Therapeutics. MarketBeat recorded 34 mentions for Pharvaris and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.73 beat Pharvaris' score of 0.48 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its share price is 333% less volatile than the broader market.

Summary

Kymera Therapeutics beats Pharvaris on 8 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Protagonist Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market.

Protagonist Therapeutics presently has a consensus target price of $147.13, suggesting a potential upside of 3.01%. Pharvaris has a consensus target price of $59.87, suggesting a potential upside of 59.43%. Given Pharvaris' higher probable upside, analysts plainly believe Pharvaris is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Protagonist Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	200.85	-$130.15M	$1.03	138.68
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Protagonist Therapeutics has a net margin of 29.40% compared to Pharvaris' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Pharvaris	N/A	-61.40%	-56.00%

In the previous week, Pharvaris had 23 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 34 mentions for Pharvaris and 11 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.65 beat Pharvaris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Pharvaris on 13 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Ionis Pharmaceuticals?

Pharvaris (NASDAQ:PHVS) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Pharvaris had 21 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 34 mentions for Pharvaris and 13 mentions for Ionis Pharmaceuticals. Pharvaris' average media sentiment score of 0.48 beat Ionis Pharmaceuticals' score of 0.33 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Pharvaris presently has a consensus target price of $59.87, suggesting a potential upside of 59.43%. Ionis Pharmaceuticals has a consensus target price of $90.80, suggesting a potential upside of 102.50%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Pharvaris has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Ionis Pharmaceuticals	$874.09M	8.53	-$381.39M	-$3.46	N/A

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharvaris has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Pharvaris' return on equity of -61.40% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Summary

Pharvaris beats Ionis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Cytokinetics?

Pharvaris (NASDAQ:PHVS) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Pharvaris has higher earnings, but lower revenue than Cytokinetics. Pharvaris is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Cytokinetics	$88.04M	98.07	-$784.96M	-$7.22	N/A

Pharvaris has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Cytokinetics	-1,321.12%	N/A	-51.01%

In the previous week, Pharvaris had 17 more articles in the media than Cytokinetics. MarketBeat recorded 34 mentions for Pharvaris and 17 mentions for Cytokinetics. Pharvaris' average media sentiment score of 0.48 beat Cytokinetics' score of 0.37 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	12 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris currently has a consensus target price of $59.87, suggesting a potential upside of 59.43%. Cytokinetics has a consensus target price of $103.37, suggesting a potential upside of 48.97%. Given Pharvaris' higher probable upside, research analysts clearly believe Pharvaris is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Cytokinetics beats Pharvaris on 7 of the 13 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHVS vs. The Competition

Export

Metric	Pharvaris	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.46B	$3.83B	$7.19B	$14.92B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-12.31	14.28	274.07	25.35
Price / Sales	N/A	1,415.89	697.80	112.38
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	7.97	15.15	10.37	6.25
Net Income	-$198.79M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-0.50%	-3.97%	-1.80%	-2.06%
1 Month Performance	6.86%	-2.60%	-1.49%	-4.80%
1 Year Performance	57.71%	37.15%	18.18%	5.47%

Pharvaris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHVS Pharvaris	3.5961 of 5 stars	$37.55 -1.3%	$59.87 +59.4%	+62.8%	$2.46B	N/A	N/A	148	Trending News Analyst Forecast Insider Trade High Trading Volume
PRAX Praxis Precision Medicines	3.0502 of 5 stars	$352.48 +0.2%	$585.95 +66.2%	+673.5%	$9.84B	$8.55M	N/A	110	Positive News
KYMR Kymera Therapeutics	1.8997 of 5 stars	$116.47 -0.8%	$128.70 +10.5%	+139.3%	$9.68B	$39.21M	N/A	170	Analyst Forecast
PTGX Protagonist Therapeutics	1.6811 of 5 stars	$145.94 +0.2%	$147.13 +0.8%	+145.6%	$9.44B	$281.99M	141.69	120
IONS Ionis Pharmaceuticals	3.2144 of 5 stars	$56.71 -2.4%	$91.50 +61.3%	-22.7%	$9.42B	$944M	N/A	1,402	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHVS) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, KYMR, PTGX, IONS, and CYTK

How does Pharvaris compare to Praxis Precision Medicines?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Summary

How does Pharvaris compare to Protagonist Therapeutics?

Summary

How does Pharvaris compare to Ionis Pharmaceuticals?

Summary

How does Pharvaris compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharvaris (PHVS) Competitors

PHVS vs. PRAX, KYMR, PTGX, IONS, and CYTK

How does Pharvaris compare to Praxis Precision Medicines?

Is PHVS or PRAX more profitable?

Which has preferable earnings and valuation, PHVS or PRAX?

Do analysts rate PHVS or PRAX?

Does the media refer more to PHVS or PRAX?

Which has more volatility and risk, PHVS or PRAX?

Do institutionals and insiders believe in PHVS or PRAX?

Summary

How does Pharvaris compare to Kymera Therapeutics?

Do analysts recommend KYMR or PHVS?

Is KYMR or PHVS more profitable?

Which has preferable earnings and valuation, KYMR or PHVS?

Does the media favor KYMR or PHVS?

Which has more volatility & risk, KYMR or PHVS?

Summary

How does Pharvaris compare to Protagonist Therapeutics?

Which has more risk and volatility, PTGX or PHVS?

Do analysts prefer PTGX or PHVS?

Which has stronger earnings and valuation, PTGX or PHVS?

Do insiders and institutionals hold more shares of PTGX or PHVS?

Is PTGX or PHVS more profitable?

Does the media favor PTGX or PHVS?

Summary

How does Pharvaris compare to Ionis Pharmaceuticals?

Does the media refer more to PHVS or IONS?

Which has more risk and volatility, PHVS or IONS?

Do analysts rate PHVS or IONS?

Which has preferable valuation & earnings, PHVS or IONS?

Do insiders & institutionals hold more shares of PHVS or IONS?

Is PHVS or IONS more profitable?

Summary

How does Pharvaris compare to Cytokinetics?

Which has more volatility and risk, PHVS or CYTK?

Which has preferable earnings & valuation, PHVS or CYTK?

Is PHVS or CYTK more profitable?

Does the media refer more to PHVS or CYTK?

Do analysts prefer PHVS or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS vs. The Competition

Pharvaris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools